Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Forbion
Deal Size : $65.0 million
Deal Type : Series A Financing
Progentos Therapeutics Closes $65 Million Series A Financing for Multiple Sclerosis
Details : The financing aims to fund the Progentos, which is developing first-in-class small molecules designed to induce remyelination of axons affected by multiple sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Forbion
Deal Size : $65.0 million
Deal Type : Series A Financing
Reset All
